蛋白质稳态
泛素
泛素连接酶
生物
细胞生物学
转移
癌症研究
伴随蛋白
基因敲除
化学
肺癌
癌细胞
伴侣(临床)
细胞骨架
效应器
癌症
肿瘤进展
泛素蛋白连接酶类
转移抑制因子
PI3K/AKT/mTOR通路
细胞迁移
入侵足纲
循环肿瘤细胞
作者
Zhenyi Wang,Huanhuan Huang,Kaizong Huang,Xiaowen Cui,Leilei Wu,Renyu Lin,Zhe Zhao,Hua Chen,Zheng Cheng,Weilin Jin,Song Chen,Jiayan Chen,Yaping Xu,Dongping Wei
标识
DOI:10.1002/advs.202509695
摘要
Metastasis is the primary challenge in lung cancer treatment. Although proteostasis supports tumor growth, the mechanism by which ubiquitin ligases reprogram chaperone networks to drive metastasis is poorly understood. In this study, it is revealed that DDB1-CUL4-associated factor (DCAF12), a substrate receptor for CUL4-RING ubiquitin ligases, regulates metastatic progression through ubiquitin-mediated proteostatic reprogramming. DCAF12 depletion suppresses tumor cell migration and stemness in vitro and reduces pulmonary/hepatic metastasis in vivo. Mechanistically, DCAF12 catalyzes the non-degradative ubiquitination of TRiC/CCT subunits, enhancing chaperonin assembly and folding of cytoskeletal effectors (β-actin/tubulin) and oncogenic clients (STAT3/Raptor/mLST8), thereby activating the YAP, STAT3, and mTOR pathways. Both genetic knockdown and pharmacological blockade (via HSF1A) of this axis potently inhibit metastasis. Clinically, DCAF12 overexpression is correlated with YAP/STAT3 activation, advanced metastasis, and poor survival. Three key insights are revealed: 1) ubiquitination-mediated TRiC/CCT regulation as a metastatic switch, 2) DCAF12 as an oncogenic proteostasis hub, and 3) therapeutic potential validated through multimodal targeting. These findings establish the DCAF12-TRiC/CCT axis as a mechanistically novel target that simultaneously disrupts cytoskeletal dynamics and oncogenic signaling, making it a promising therapeutic strategy for metastatic lung cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI